The Problem

The client R&D team was in a race to launch a new immunotherapy within a new indication, which over-indexed in ethnic populations. They didn’t see the volume of patients needed for their phase 2 trial, and recruiting was languishing.

The Solution

CHM recognized that these patients wanted to be treated by their community oncologist and were not open to transitioning their care to an academic institution. Our team crafted a refined community-based trial recruitment strategy.

The Results

The client doubled enrollment — fulfilling trial patient requirements within 8 months and ahead of schedule.